This randomized phase I trial is studying the side effects and best dose of
O(6)-benzylguanine when given together with ifosfamide and to see how well it works compared
to ifosfamide alone in treating patients with unresectable metastatic solid tumors. Drugs
used in chemotherapy, such as ifosfamide and O(6)-benzylguanine, work in different ways to
stop tumor cells from dividing so they stop growing or die. Combining ifosfamide with
O(6)-benzylguanine may kill more tumor cells
I. Determine the maximum tolerated dose of O6-benzylguanine when administered with standard
high-dose ifosfamide in patients with unresectable, metastatic solid tumors.
II. Determine whether O6-benzylguanine enhances ifosfamide-mediated myelosuppression in
patients treated with this regimen.
III. Determine the relationship between O6-benzylguanine dose and intra-individual
variability in the degree of myelosuppression in patients treated with this regimen.
IV. Determine the safety and toxicity of this regimen in these patients.
I. Determine the effect of O6-benzylguanine on pharmacodynamic endpoints, including
apoptosis and DNA damage, in patients treated with this regimen.
II. Determine the pharmacokinetics of O6-benzylguanine and its major metabolite, 8-oxoBG, in
patients treated with this regimen.
OUTLINE: This is a randomized, open-label, multicenter, dose-escalation study of
Course 1: All patients receive high-dose ifosfamide IV continuously over 72 hours on days
Course 2: Patients are randomized to 1 of 2 treatment arms.
Arm I: Patients receive high-dose ifosfamide as in course 1.
Arm II: Patients receive a bolus dose of O6-benzylguanine (BG) IV over 1 hour on day 1
followed by BG IV continuously and high-dose ifosfamide IV continuously over 72 hours on
days 1-3. Cohorts of 6-12 patients receive escalating doses of BG (administered as a bolus
and as a continuous infusion during course 2) until the maximum tolerated dose (MTD) is
determined. The MTD is defined as the dose preceding that at which 3 of 6 or 4 of 12
patients experience dose-limiting toxicity.
Course 3 and all subsequent courses: All patients receive BG (at the MTD determined in
course 2, arm II) and high-dose ifosfamide as in course 2, arm II. In all courses, all
patients also receive filgrastim (G-CSF) beginning on day 5 and continuing until blood
counts recover. In all courses and in both arms, treatment repeats every 21 days in the
absence of disease progression or unacceptable toxicity.
- Histologically confirmed solid tumor
- Unresectable, metastatic disease
- No primary tumors
- Eligible for high-dose ifosfamide-based therapy
- No known brain metastases
- Performance status - ECOG 0-1
- Performance status - Karnofsky 70-100%
- More than 12 weeks
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- AST and ALT ≤ 2.5 times upper limit of normal
- Bilirubin normal
- Creatinine normal
- Creatinine clearance ≥ 60 mL/min
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 4 weeks after study
- No history of allergic reaction attributed to compounds of similar chemical or
biological composition to O6-benzylguanine or other study agents
- No concurrent uncontrolled illness
- No active or ongoing infection
- No psychiatric illness or social situation that would preclude study compliance
- More than 24 hours since prior colony-stimulating factors (filgrastim [G-CSF] or
- No prior hematopoietic stem cell transplantation
- No concurrent pegfilgrastim
- No concurrent immunotherapy
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
- No other concurrent chemotherapy
- No concurrent hormonal therapy
- More than 4 weeks since prior radiotherapy and recovered
- No concurrent therapeutic radiotherapy
- More than 4 weeks since prior anticancer therapy
- No more than 2 prior cytotoxic regimens
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No other concurrent anticancer agents or therapies
- No other concurrent investigational agents